Zimmer® Natural Nail® (ZNN) Bactiguard Tibia Post-Market Clinical Follow-up Study
NCT ID: NCT05022485
Last Updated: 2025-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2022-04-11
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary objectives are confirmation of safety, performance and clinical benefits of ZNN Bactiguard implant and related instrumentation12 months after fracture fixation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ZNN Bactiguard Retrograde Femoral Nails PMCF Study
NCT05276674
ZNN Bactiguard Cephalomedullary Nails PMCF Study
NCT05362864
ZNN Bactiguard Antegrade Femoral Nails PMCF Study
NCT05339360
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
NCT05421741
Clinical Follow-up to Evaluate the Clinical Usefulness of Gentamicin-coated Titanium Nails in Tibia Fractures
NCT01282294
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll patients that will be implanted with the Zimmer Natural Nail Bactiguard Tibia device and retrospective controls implanted with standard titanium-alloy tibia nails.
500 tibias will be recruited at maximum 15 sites and allocated on a 1:1 ratio into an:
* investigational group (prospective/consecutive series of 250 tibias treated with ZNN Bactiguard tibia)
* a control group (retrospective series of 250 tibias treated with uncoated titanium-alloy tibia nail - data collection will be retrospective, these subjects will not have to undergo any study-related procedure).
The primary endpoint is the Fracture Related Infection (FRI) rate in the study population 12 months after fracture fixation.
The secondary endpoint is the confirmation of safety, performance and clinical benefits of ZNN Bactiguard implant and related instrumentation through the following measure systems:
* Radiologic (RUST) \& clinical (FIX-IT) fracture healing 12 months after fracture fixation (performance).
* Patients' outcomes assessed by the Oxford Knee Score 12 months after fracture fixation (clinical benefits).
* EQ5D-5L (patients' quality of life).
* Incidence and frequency of adverse events (safety).
Data will be collected at 2 weeks, 3 months, 6 months and 1 year after fracture fixation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Investigational group
Subjects that will be implanted with the ZNN Bactiguard tibia device.
ZNN Bactiguard tibia
Tibia fracture fixation
Control group
Subjects that have received an uncoated titanium-alloy tibia nail in the past (data collection is retrospective; patients will not have to undergo any study-related procedure).
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZNN Bactiguard tibia
Tibia fracture fixation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has signed IRB/EC-approved informed consent (if applicable for retrospective controls, based on local requirements).
* Patient suffered primary tibia fracture (monolateral or bilateral) at high risk of infection, eligible for fixation by intramedullary (IM) nailing (standard or suprapatellar approach) and meets at least one of the following conditions:
* Open fractures (incl. gunshot fractures): Gustilo Type I, II, III A and III B.
* Delayed treatment (initial treatment by external fixation due to swelling/ high energy trauma followed by definitive treatment by intramedullary nail).
* Fracture associated with ipsilateral leg compartment syndrome treated with fasciotomy wound(s).
* Closed fractures with severe tissue damage: Tscherne grade C2 and C3.
* Patient:
* will be treated with ZNN Bactiguard tibia for inclusion in investigational group (retrospective enrollment is allowed up to 1st follow-up visit);
* was treated with uncoated (conventional) titanium-alloy intramedullary tibia nail for inclusion in control group;
Exclusion Criteria
* Patient is not expected to survive follow-up schedule.
* Patient is anticipated to be non-compliant to the study protocol.
* Patient has a mental or neurological condition or alcohol/drug addiction that will not allow for proper informed consent and/or participation in follow-up program.
* Patient is a prisoner.
* Patient is known to be pregnant and/or breastfeeding.
* Patient suffered tibia fracture that meets any of the following conditions:
* Pathologic fracture.
* Gustilo Type IIIC open fracture.
* Patient has multisegmented fracture NOT eligible for fixation by intramedullary nailing.
* Patients with wound closure more than 10 days after injury.
* Besides IM nail, patient requires additional tibia fixation by plate (additional tibia fixation by screw(s) and/or fibula plate fixation are allowed).
* Concomitant with fracture, patient suffered head injury with Abbreviated Injury Score (AIS) ≥ 3.
* For control group:
* patient doesn't have all the minimum required data available:
1. demographic information
2. injury classification
3. FRI information
4. operative report and device information
5. radiographic analyses (until fracture healing or confirmation of non-union leading to reoperation)
* Tibia medullary canal is obliterated by a previous fracture or tumor\*
* Tibia bone shaft having excessive bow or a deformity\*
* Lack of bone substance or bone quality, which makes stable seating of the nail implant impossible\*
* All concomitant diseases that can impair the operation, functioning or the success of the nail implant\*
* Insufficient blood circulation\*
* Skeletally immature patients\*
* Infection\*
* ZNN Bactiguard tibia contraindication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zimmer Biomet
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilie Rohmer
Role: STUDY_DIRECTOR
Clin Ops Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tirolkliniken Innsbruck
Innsbruck, , Austria
Hôpital Ambroise-Paré
Boulogne-Billancourt, , France
Hôpitaux Universitaires de Marseille Nord
Marseille, , France
Universitätsklinikum Marburg
Marburg, Hesse, Germany
Universitätsklinikum Leipzig
Leipzig, , Germany
Universitätsklinikum Regensburg
Regensburg, , Germany
AOU Policlinico di Bari
Bari, , Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
Tygerberg Hospital
Cape Town, , South Africa
Groote Schuur Hospital
Cape Town, , South Africa
Hospital Universitario Valle de Hebrón
Barcelona, Catalonia, Spain
Kantonsspital Winterthur
Winterthur, Canton of Zurich, Switzerland
Royal Infirmary of Edinburgh
Edinburgh, , United Kingdom
Leeds General Infirmary
Leeds, , United Kingdom
The Royal London Hospital
London, , United Kingdom
King's College Hospital NHS Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Volker Alt, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMG2020-32T
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.